0
Applied Therapeutics, Inc. Banner Image

Applied Therapeutics, Inc. has reached its limit for free report views

Work for Applied Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Applied Therapeutics, Inc.

  • Ticker APLT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Applied Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in New York City, New York
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease. The CompanyMore initiated a pivotal Phase 1/2 clinical trial in June 2019, read out positive top-line biomarker data in adult Galactosemia patients in January 2020 and announced full data from the trial in April 2020. A pediatric Galactosemia study commenced in June 2020 and is currently ongoing. The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM in September 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.
Applied Therapeutics, Inc.

Most Recent Annual Report

Applied Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Applied Therapeutics, Inc. has reached its limit for free report views.